deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03404193

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm

Sponsor: M.D. Anderson Cancer Center

Conditions Acute Myeloid Leukemia Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Blastic Plasmacytoid Dendritic Cell Neoplasm Chronic Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Recurrent Acute Biphenotypic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelomonocytic Leukemia Recurrent Mixed Phenotype Acute Leukemia Refractory Acute Myeloid Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Chronic Myelomonocytic Leukemia Refractory Mixed Phenotype Acute Leukemia
Interventions Decitabine Laboratory Biomarker Analysis Venetoclax
Updated 24 times since 2018 Last updated: Mar 6, 2026 Started: Jan 18, 2018 Primary completion: Mar 5, 2026 Completion: Mar 5, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

\<75% participation

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

Other Acute Myeloid Leukemia trials with similar outcome

Browse all Acute Myeloid Leukemia trials

This PHASE2 trial investigates Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and is currently terminated or withdrawn. M.D. Anderson Cancer Center leads this study, which shows 24 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshot~Apr 2025 – ~Oct 2025 · 6 months · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Mar 2026 · 59 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

24 versions recorded

  1. Mar 2026 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jan 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 19 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  5. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  6. Jul 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  7. Nov 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  9. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE2

  11. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  13. Jan 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  14. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  15. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  16. Sep 2018 — May 2019 [monthly]

    Recruiting PHASE2

  17. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  18. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  19. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations